On December 20, 2023, Baiyunshan issued the "Announcement of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. on Guangzhou Guangyao** Equity Investment Partnership (Limited Partnership) to Participate in the Investment and Establishment of Sub-investment and Related Party Transactions", Baiyunshan Pharmaceutical Group invested in the establishment of Guangyao**, with an investment of no more than 6RMB 9 billion to subscribe to Guangzhou Pharmaceutical Venture Capital**. GPC Capital is the manager and general partner of GPC Ventures. The investment constitutes a related party transaction, which has been deliberated and approved by the board of directors and the board of supervisors, and does not constitute a material asset restructuring. In the past 12 months, including this connected transaction, the cumulative amount of related party transactions between Baiyunshan and Guangzhou Pharmaceutical Group and its subsidiaries is approximately 50.4 billion yuan, accounting for 157%。The main risks include the failure of GPC Venture Capital** to be established in full and on time, the failure to find suitable investment targets and the failure of investment returns to meet expectations. GPC Capital is the general partner, executive partner and manager of GPC Ventures. The registered capital of the special parent company is 600,000 yuan, the establishment date is August 17, 2023, and the business scope includes private equity investment, investment management, asset management and other activities. The proportion of capital contribution in Guangzhou Industrial Investment Private Equity Management is 999833%, subscribed capital contribution of 599900000 yuan, accounting for 999833%；Guangzhou Industrial Investment Private Equity Management invested 1 million yuan, accounting for 00167%。
The scale of the partnership shall not exceed 1 billion yuan, and the investment areas mainly include medicine, medical devices, medical services and other medical and health projects, and the investment methods include direct investment or through special purpose vehicles. The management model is that GPC Capital is the executive partner and the first manager of the partnership. The investment decision-making committee is composed of five members, of which one is recommended by GPC Capital, and two are recommended by GPP** and the special parent of production and investment. The income distribution shall be distributed according to the proportion of the paid-in capital contribution of all partners in the partnership, and the loss sharing shall be shared by the partners according to the proportion of paid-in capital contribution. The management fee is 1% of the total paid-in capital contribution during the investment period, and 1% of the unrecovered investment principal during the exit period. The exit methods include the withdrawal of the investee enterprise after the direct or indirect initial public offering and listing of the investee enterprise in China or abroad, and the withdrawal of part of the investee enterprise or its affiliated listed companies. The board of directors of Guangzhou Baiyunshan Pharmaceutical Group deliberated and approved the proposal of Guangzhou Guangzhou Pharmaceutical ** Equity Investment Partnership to subscribe for the share of Guangzhou Pharmaceutical Venture Capital ** Limited Partnership and related party transactions. The affiliated directors abstained from voting, and all independent directors agreed to the related party transaction. The Board of Supervisors also deliberated and approved the proposal. The independent directors acknowledged that the transaction was fair, just and reasonable. The investment of GPC ** in subscribing to the limited partnership share of GPC Venture Capital ** is in line with the investment direction of GPC**, which is conducive to diversifying investment risks and improving investment efficiency, and will promote the company to accelerate the transformation and upgrading in the field of biomedical and health industry and achieve rapid development.
Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. was listed on the Shanghai Stock Exchange on February 6, 2001, and its main business is the research, development, manufacturing and sales of Chinese patent medicines. In the national economic industry, it belongs to the manufacturing industry and the pharmaceutical manufacturing industryIn terms of Shenwan industry classification, it belongs to the major category of medicine and biology and the small category of traditional Chinese medicine. As of October 25, 2023, the actual controller of the company is the people of Guangzhou**.
As of December 19, 2023**, the company's share price is 2848 yuan shares, with a circulating market value of 4630.3 billion yuan.
Announcement**: Disclaimer: This article is written by the robot, jointly incubated by Pencil Road and Hanxin Society, and the main data is provided by Hanguang Suwen. The content and data in this article are for reference only and do not constitute investment advice.